Pannu Neesh, McBrien Kerry A, Tan Zhi, Ahmad Nasreen, Bignell Coralea, Benterud Eleanor, Palechuk Taylor, Harrison Tyrone G, Manns Braden J, Scott-Douglas Nairne, James Matthew T
Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
J Am Soc Nephrol. 2025 Mar 1;36(3):441-450. doi: 10.1681/ASN.0000000537. Epub 2024 Oct 24.
A risk-guided intervention improved adherence to processes of care for AKI survivors. Further supports are necessary to improve uptake of processes of care for AKI survivors in primary care.
AKI is associated with development and progression of CKD. Gaps in recommended care for CKD are common after AKI.
In this randomized controlled trial conducted in Alberta, Canada, we allocated adults hospitalized with Kidney Disease Improving Global Outcomes (KDIGO) stage 2 or greater AKI to a risk-guided, transition of care intervention versus usual practices at the time of hospital discharge. For people in the intervention group, we used a validated risk index to predict risk of severe CKD after AKI. People at low risk (<1%) received patient education alone. People at medium risk received additional clinical guidance, provided to their primary care physician. People at high risk (>10%) were referred to nephrology. The primary outcome was the proportion of patients who received treatment with an angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB), statin, and nephrology specialist follow-up within 90 days of discharge.
One hundred fifty-five patients were recruited; the mean (SD) age was 60 (15) years, 91 (60%) were male, and 96 (62%) had eGFR <60 ml/min per 1.73 m or urine albumin-creatinine ratio >30 mg/g at discharge. The proportion of participants who received ACE-I/ARB, statin treatment, and nephrologist follow-up was 28% in the intervention group versus 3% in the usual care group (absolute risk difference [RD], 25%; 95% confidence interval [CI], 15% to 36%). The use of ACE-I or ARB in participants with urine albumin-creatinine ratio >300 mg/g or diabetes was greater in the high-risk group with the intervention versus usual care (RD, 37%; 95% CI, 6% to 67%), as was statin use among those with CKD (RD, 30%; 95% CI, 5% to 56%) and nephrologist follow-up for those with sustained eGFR <30 ml/min per 1.73 m at discharge (RD, 78%; 95% CI, 56% to 100%). Hyperkalemia was more frequent in the intervention group (RD, 10%; 95% CI, 9% to 19%).
A risk-guided intervention for patients hospitalized with AKI increased recommended processes of care for CKD for high-risk patients after hospital discharge.
: Improving Post Discharge Care after Acute Kidney Injury (AFTER AKI), NCT02915575.
一项风险导向干预措施提高了急性肾损伤(AKI)幸存者对护理流程的依从性。需要进一步支持以提高初级保健中AKI幸存者对护理流程的接受度。
AKI与慢性肾脏病(CKD)的发生和进展相关。AKI后,CKD推荐护理存在差距很常见。
在加拿大艾伯塔省进行的这项随机对照试验中,我们将因肾脏病改善全球预后(KDIGO)2期或更严重AKI住院的成年人,在出院时分配到风险导向的护理过渡干预组或常规治疗组。对于干预组的患者,我们使用经过验证的风险指数来预测AKI后发生严重CKD的风险。低风险(<1%)的患者仅接受患者教育。中度风险的患者会获得额外的临床指导,并提供给他们的初级保健医生。高风险(>10%)的患者会被转诊至肾脏病科。主要结局是出院后90天内接受血管紧张素转换酶抑制剂(ACE-I)或血管紧张素II受体阻滞剂(ARB)治疗、他汀类药物治疗以及肾脏病专科随访的患者比例。
招募了155名患者;平均(标准差)年龄为60(15)岁,91名(60%)为男性,96名(62%)出院时估算肾小球滤过率(eGFR)<60 ml/min/1.73m²或尿白蛋白肌酐比值>30 mg/g。干预组接受ACE-I/ARB、他汀类药物治疗和肾脏病专科随访的参与者比例为28%,而常规护理组为3%(绝对风险差异[RD],25%;95%置信区间[CI],15%至36%)。与常规护理相比,干预组中尿白蛋白肌酐比值>300 mg/g或患有糖尿病的参与者使用ACE-I或ARB 的比例更高(RD,37%;95% CI,6%至67%),CKD患者使用他汀类药物的比例也是如此(RD,30%;95% CI,5%至56%),出院时持续eGFR<30 ml/min/1.73m²的患者接受肾脏病专科随访的比例也是如此(RD,78%;95% CI,56%至100%)。干预组高钾血症更常见(RD,10%;95% CI,9%至19%)。
对因AKI住院的患者进行风险导向干预,增加了出院后高危患者对CKD推荐护理流程的接受度。
改善急性肾损伤后出院护理(AFTER AKI),NCT02915575。